Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Querol Cano, Laia"'
Autor:
Querol Cano, Laia, Tagit, Oya, Dolen, Yusuf, van Duffelen, Anne, Dieltjes, Shannon, Buschow, Sonja I., Niki, Toshiro, Hirashima, Mitsuomi, Joosten, Ben, van den Dries, Koen, Cambi, Alessandra, Figdor, Carl G., van Spriel, Annemiek B.
Publikováno v:
In iScience 20 December 2019 22:240-255
Publikováno v:
Nature Reviews Immunology; March 2024, Vol. 24 Issue: 3 p193-212, 20p
Autor:
Santalla Méndez, Rui, Rodgers Furones, Andrea, Classens, René, Fedorova, Kristina, Haverdil, Manon, Canela Capdevila, Marta, van Duffelen, Anne, Spruijt, Cornelia G., Vermeulen, Michiel, ter Beest, Martin, van Spriel, Annemiek B., Querol Cano, Laia
Publikováno v:
Cellular & Molecular Life Sciences; Oct2023, Vol. 80 Issue 10, p1-20, 20p
Autor:
Dunlock, Vera-Marie E., Arp, Abbey B., Singh, Simar Pal, Charrin, Stéphanie, Nguyen, Viet, Jansen, Erik, Schaper, Fleur, Beest, Martin Ter, Zuidscherwoude, Malou, van Deventer, Sjoerd J., Nakken, Britt, Szodoray, Peter, Demaria, Maria C., Wright, Mark D., Querol Cano, Laia, Rubinstein, Eric, van Spriel, Annemiek B.
Publikováno v:
Dunlock, Vera-Marie E. Arp, Abbey B. Singh, Simar Pal Charrin, Stéphanie Nguyen, Viet Jansen, Erik Schaper, Fleur Beest, Martin Ter Zuidscherwoude, Malou van Deventer, Sjoerd J. Nakken, Britt Szodoray, Peter Demaria, Maria C. Wright, Mark D. Querol Cano, Laia Rubinstein, Eric van Spriel, Annemiek B. . Tetraspanin CD53 controls T cell immunity through regulation of CD45RO stability, mobility, and function. Cell reports. 2022, 39:111006(13), 1-27
Cell reports
Cell reports
Externí odkaz:
http://hdl.handle.net/10852/99555
Autor:
Querol Cano, Laia, Lavery, Derek N., Sin, Soraya, Spanjaard, Emma, Brooke, Greg N., Tilman, Jessica D., Abroaf, Ahmed, Gaughan, Luke, Robson, Craig N., Heer, Rakesh, Mauri, Francesco, de Rooij, Johan, Driouch, Keltouma, Bevan, Charlotte L.
Publikováno v:
Molecular Oncology, 9(1), 295. Elsevier
Prostate cancer is an androgen receptor (AR)-dependent malignancy at initiation and progression, therefore hormone therapy is the primary line of systemic treatment. Despite initial disease regression, tumours inevitably recur and progress to an adva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::425c5331fbdd9a6afc4eeaaf9db494d6
http://hdl.handle.net/10044/1/21847
http://hdl.handle.net/10044/1/21847
Publikováno v:
PLoS ONE; Sep2013, Vol. 8 Issue 9, p1-11, 11p
Publikováno v:
Molecular & Cellular Endocrinology. Apr2013, Vol. 369 Issue 1/2, p52-62. 11p.
Autor:
Dunlock VE; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525GA Nijmegen, the Netherlands., Arp AB; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525GA Nijmegen, the Netherlands., Singh SP; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525GA Nijmegen, the Netherlands., Charrin S; Sorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, 75013 Paris, France., Nguyen V; Université Paris-Saclay, INSERM, UMS33, 94800 Villejuif, France., Jansen E; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525GA Nijmegen, the Netherlands., Schaper F; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525GA Nijmegen, the Netherlands., Beest MT; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525GA Nijmegen, the Netherlands., Zuidscherwoude M; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525GA Nijmegen, the Netherlands., van Deventer SJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525GA Nijmegen, the Netherlands., Nakken B; Department of Immunology, Oslo University Hospital Rikshospitalet and University of Oslo, NO-0424 Oslo, Norway; K.G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Szodoray P; Department of Immunology, Oslo University Hospital Rikshospitalet and University of Oslo, NO-0424 Oslo, Norway; K.G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Demaria MC; Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Melbourne, VIC 3004, Australia., Wright MD; Department of Immunology, Monash University, Alfred Medical Research and Education Precinct, Melbourne, VIC 3004, Australia., Querol Cano L; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525GA Nijmegen, the Netherlands., Rubinstein E; Sorbonne Université, INSERM, CNRS, Centre d'Immunologie et des Maladies Infectieuses, CIMI-Paris, 75013 Paris, France., van Spriel AB; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525GA Nijmegen, the Netherlands. Electronic address: annemiek.vanspriel@radboudumc.nl.
Publikováno v:
Cell reports [Cell Rep] 2022 Jun 28; Vol. 39 (13), pp. 111006.
Autor:
Mans LA; Institute of Biology, Leiden University, Sylviusweg 72, 2333 BE, Leiden, The Netherlands., Querol Cano L; Institute of Biology, Leiden University, Sylviusweg 72, 2333 BE, Leiden, The Netherlands.; Radboud Institute for Molecular Life Sciences - Tumour immunology department, Geert Grooteplein 28, 6525 GA, Nijmegen, The Netherlands., van Pelt J; Institute of Biology, Leiden University, Sylviusweg 72, 2333 BE, Leiden, The Netherlands., Giardoglou P; Institute of Biology, Leiden University, Sylviusweg 72, 2333 BE, Leiden, The Netherlands., Keune WJ; Department of Biochemistry, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Haramis AG; Institute of Biology, Leiden University, Sylviusweg 72, 2333 BE, Leiden, The Netherlands. a.haramis@biology.leidenuniv.nl.
Publikováno v:
Scientific reports [Sci Rep] 2017 Aug 04; Vol. 7 (1), pp. 7327. Date of Electronic Publication: 2017 Aug 04.
Autor:
Reebye V; Androgen Signaling Laboratory, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, United Kingdom., Querol Cano L, Lavery DN, Brooke GN, Powell SM, Chotai D, Walker MM, Whitaker HC, Wait R, Hurst HC, Bevan CL
Publikováno v:
Molecular endocrinology (Baltimore, Md.) [Mol Endocrinol] 2012 Oct; Vol. 26 (10), pp. 1694-706. Date of Electronic Publication: 2012 Aug 16.